Allogene Therapeutics (ALLO)
(Delayed Data from NSDQ)
$2.51 USD
+0.01 (0.40%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $2.52 +0.01 (0.40%) 5:26 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
Allogene Therapeutics, Inc. [ALLO]
Reports for Purchase
Showing records 21 - 40 ( 215 total )
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology -Healthcare Coverage Update
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Updated ALLO-501(A) Results; Competitive Landscape Updates; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ALLO-501(A) Updated Phase 1 Data at ASCO; 1Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ALLO-316 AACR Data Consistent With Prior Release; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department